company background image
2315 logo

Biocytogen Pharmaceuticals (Beijing) SEHK:2315 Stock Report

Last Price

HK$7.50

Market Cap

HK$3.0b

7D

-7.1%

1Y

-63.9%

Updated

23 Jun, 2024

Data

Company Financials +

Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

SEHK:2315 Stock Report

Market Cap: HK$3.0b

2315 Stock Overview

A biotechnology company, engages in the research and development of antibody-based drugs in the People’s Republic of China, the United States, and internationally.

2315 fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Biocytogen Pharmaceuticals (Beijing)
Historical stock prices
Current Share PriceHK$7.50
52 Week HighHK$21.50
52 Week LowHK$5.74
Beta0
11 Month Change-21.55%
3 Month Change-13.79%
1 Year Change-63.94%
33 Year Changen/a
5 Year Changen/a
Change since IPO-71.15%

Recent News & Updates

Is Biocytogen Pharmaceuticals (Beijing) (HKG:2315) A Risky Investment?

May 08
Is Biocytogen Pharmaceuticals (Beijing) (HKG:2315) A Risky Investment?

Biocytogen Pharmaceuticals (Beijing) Co., Ltd.'s (HKG:2315) Price Is Right But Growth Is Lacking

Apr 03
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.'s (HKG:2315) Price Is Right But Growth Is Lacking

Recent updates

Is Biocytogen Pharmaceuticals (Beijing) (HKG:2315) A Risky Investment?

May 08
Is Biocytogen Pharmaceuticals (Beijing) (HKG:2315) A Risky Investment?

Biocytogen Pharmaceuticals (Beijing) Co., Ltd.'s (HKG:2315) Price Is Right But Growth Is Lacking

Apr 03
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.'s (HKG:2315) Price Is Right But Growth Is Lacking

Shareholder Returns

2315HK BiotechsHK Market
7D-7.1%-2.5%0.6%
1Y-63.9%-33.0%2.4%

Return vs Industry: 2315 underperformed the Hong Kong Biotechs industry which returned -33% over the past year.

Return vs Market: 2315 underperformed the Hong Kong Market which returned 2.4% over the past year.

Price Volatility

Is 2315's price volatile compared to industry and market?
2315 volatility
2315 Average Weekly Movement10.0%
Biotechs Industry Average Movement9.0%
Market Average Movement7.2%
10% most volatile stocks in HK Market15.1%
10% least volatile stocks in HK Market3.7%

Stable Share Price: 2315's share price has been volatile over the past 3 months.

Volatility Over Time: 2315's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20091,066Yuelei Shenbiocytogen.com.cn

Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of antibody-based drugs in the People’s Republic of China, the United States, and internationally. Its core products are YH001, a recombinant humanized anti-cytotoxic t-lymphocyte associated protein 4 immunoglobulin G1 (IgG1) monoclonal antibody, which has completed Phase I clinical trial for the treatment of patients with advanced solid tumors; and YH003, a humanized IgG2 agonistic monoclonal antibody that is in Phase II clinical trial for the treatment of unresectable/metastatic mucosal melanoma and pancreatic duct adenocarcinoma, and Phase I clinical trial for the treatment of solid tumors. The company also develops YH002, a recombinant humanized IgG1 antibody that targets the human tumor necrosis factor receptor superfamily, member 4 receptor, which is Phase I clinical trial; YH004, a humanized anti-4- tumor necrosis factor receptor superfamily, member 9 IgG1 antibody that is in Phase I clinical trial for the treatment of advanced solid tumors and relapsed/refractory non-Hodgkin’s lymphoma; and YH008, an anti-PD-1 x cluster of differentiation 40 (CD40) bispecific antibody that is in Phase I clinical trial for the treatment of solid tumors.

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Fundamentals Summary

How do Biocytogen Pharmaceuticals (Beijing)'s earnings and revenue compare to its market cap?
2315 fundamental statistics
Market capHK$3.00b
Earnings (TTM)-HK$411.65m
Revenue (TTM)HK$770.64m

3.9x

P/S Ratio

-7.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2315 income statement (TTM)
RevenueCN¥716.91m
Cost of RevenueCN¥206.00m
Gross ProfitCN¥510.91m
Other ExpensesCN¥893.86m
Earnings-CN¥382.95m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.96
Gross Margin71.27%
Net Profit Margin-53.42%
Debt/Equity Ratio44.4%

How did 2315 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.